Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pheochromocytoma.

M S Eigelberger1, Q Y Duh

  • 1Department of Surgery, University of California, San Francisco/Mt. Zion Medical Center, University of California, Campus Box 1674, San Francisco, CA 94143-1674, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Invasion of metastatic human follicular thyroid cancer is inhibited via antagonism of protein kinase C.

Cancer letters·2008
Same author

Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?

World journal of surgery·2006
Same author

Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome.

Thyroid : official journal of the American Thyroid Association·2004
Same author

[Transfection of follicular thyroid gland carcinoma cells with human TSH receptor changes growth, invasion and adhesion].

Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same author

Laparoscopic live donor nephrectomy at the University of California San Francisco.

Clinical transplants·2002
Same author

Recurrent or persistent thyroid cancer of follicular cell origin.

Current treatment options in oncology·2002
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Surgical resection is the definitive treatment for pheochromocytoma. Advances in medical management and surgical techniques like laparoscopic resection have significantly improved patient outcomes and reduced risks.

Area of Science:

  • Endocrinology
  • Surgical Oncology

Background:

  • Pheochromocytoma, a rare tumor, historically carried high surgical risks.
  • Effective management requires addressing associated hypertension and hypovolemia preoperatively.

Purpose of the Study:

  • To review the current standards of care for pheochromocytoma treatment.
  • To highlight advancements in surgical approaches and their impact on patient outcomes.

Main Methods:

  • Review of current medical literature and surgical outcomes for pheochromocytoma.
  • Analysis of the evolution of diagnostic and therapeutic strategies.

Main Results:

  • Surgical resection remains the primary curative therapy for pheochromocytoma.
  • Improved preoperative management and anesthetic care have decreased operative mortality to below 5%.

Related Experiment Videos

  • Minimally invasive laparoscopic resection is now the standard of care, reducing morbidity.

    • Conclusions:

    • Laparoscopic resection offers a reduced morbidity approach for most pheochromocytoma cases.
    • Open resection may still be necessary for large or locally invasive tumors.